AzTrials
AzTrials

Breast Milk CollectionMAINHEALTHNCT05111990

Human Milk and Its Effect on Infant's Metabolism and Infant Gut Microbiome

An observational study of Breast Milk Collection and Human Milk/Breastfeeding, run by University of Aarhus at 1 site in Denmark.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

This protocol explains the MAINHEALTH cohort. The study examine the influence of maternal health parameters on human breast milk composition and integrates milk phenotype with infant metabolism and infant gut microbial content and metabolism. Read more about this study

Who is it for?
Any age, women onlyHealthy volunteers can take part
How many people
168 participants
Where
1 siteDenmark
Study dates
1 Jun 2019to 30 Apr 2028
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • Women only
  • Healthy volunteers accepted
  • Child, Adult, Older adult

Study population: Residence in Aarhus area is necessary and Aarhus University Hospital has to be the place of giving birth. This is due to samples being collected by midwifes during labor and when study personnel collect samples in study participants' homes.

Who may be able to join

  • Residing in Aarhus area
  • Above 18 years of age
  • BMI above 18.5 kg/m2
  • Intention to breastfeed the first four to six months following birth
  • Be able to communicate in Danish
  • Infants born after gestational age 37 weeks
  • Infants with a birth weight between 2500 g and 5000 g

Who cannot join

  • Smoking
  • Multiple gestation
  • Suffering from the following chronic diseases that demands medical treatment: diabetes mellitus, celiac disease, inflammatory bowel disease (Chrohn's disease or ulcerosa colitis)
  • Taking medicaments for irritable bowel syndrome
  • Taking medicine for metabolic disorders
  • Taking medicine for psychological disorders
Show all 11Show fewer
  • Have had gastric bypass surgery
  • Planned caesarean section
  • Received antibiotics after week 12 in their pregnancy
  • Utilizing significant amount of infant formula following birth
  • Inborn errors of metabolism

Trial locations and contacts

1 site in 1 country.

Denmark1 site
  • Aarhus University

    Aarhus, 8200

Other trials in Denmark

About this study

Official title: The Influence of Maternal Health on Human Breast Milk Composition With Potential Downstream Effects on Infant Metabolism and Gut Colonization

This protocol explains the MAINHEALTH cohort. The study examine the influence of maternal health parameters on human breast milk composition and integrates milk phenotype with infant metabolism and infant gut microbial content and metabolism.

Read the detailed description

The birth of a living human being is the result of an approximately nine-month pregnancy in which the developing foetus has taken exactly the building blocks necessary to grow and develop from its mother. However, growth and development continues in multiple dimensions at an increasing pace after birth. The nutrition in the first 1,000 days from conception to the child's 2nd birthday plays a pivotal role in shaping the future health of the child. Yet, little is known of how breast milk components vary due to maternal factors or of the biological mechanisms behind the beneficial actions of many breast milk nutrients. The investigators propose to overcome these obstacles by combining specialties to give a more complete account of what breast milk is (major and minor milk constituents and microbiota), how it affects the infants directly or indirectly through breast milk-gut microbiome interactions and by which mechanisms. In this study longitudinal samples from 200 mother-infant dyads during the first year of life across three groups of pregestational maternal BMI; normal weight (BMI 18.5-24.99), overweight (BMI 25-30), and obese (BMI >30) are collected. The samples give a comprehensive record of what the infant has ingested (milk samples) and how the infant and infant gut microbiome responds to this (infant urine and feces). Maternal diet in pregnancy and at milk sample deliveries are recorded through a 24h online food recall and diary system. Maternal health attributes will, besides BMI, be analysed through clinical blood biochemistry parameters. Follow-up samples and infant dietary intake as the infant grows allow investigating how early life diet shaped infant growth and gut colonization more long term. The investigators have formed an experienced team of scientists within metabolomics, microbiology and medicine, holding leading positions within their respective fields in Denmark. The novelty in the study is the interdisciplinarity, unique study design and the emphasis to integrate a number of dynamic measurements thereby offering the ability to identify the factors in breast milk affecting infant metabolism and gut colonization. Knowing this enable the optimization of infant formula.

The research questions asked in this project are three-fold.

  • First, the investigators want to determine the variability of breast milk nutrients by application of multi-omics (metabolomics, proteomics and glycomics). The production of human breast milk has a high maternal metabolic cost. Thus, hypothesis is that maternal health attributes (metabolic dysfunction or obesity) influence which breast milk nutrients are made available to the infant.
  • Second, the investigators want to establish the microbiome of breast milk. Maternal obesity can lead to an apparent gut microbial ecology and increases the risk of obesity for the child. Thus, the hypothesis is that maternal obesity confers distinct microorganisms to the infant.
  • Third, the investigators want to identify biological mechanisms for how breast milk nutrients are metabolised in the infants. Infants exclusively breast-feeding offer total compliance. Thus, the hypothesis is that by deconstructing breast milk components and markers of infant metabolism through comprehensive analysis of infant urine and feces, bioactivity of breast milk nutrients can be elucidated.
Keywords
milk metabolites, multi-omics, gut microbiome
Medical subject headings
Breast Milk Expression

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT05111990
Study groupRoleWhat they receive
Maternal pre-gestational BMI 18.5<25Not described
Maternal pre-gestational BMI 25<30Not described
Maternal pre-gestational BMI >30Not described

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Metabolite profile of human milk

    Human milk metabolites by Nuclear Magnetic Resonance (NMR) spectroscopy. Data will be analysed as absolute concentrations of milk metabolites; how milk metabolite profiles are related to mother's blood chemistry, milk microbial profiles, milk oligosaccharides, infant urine metabolome, and infant fecal microbiomes will be explored using multivariate analyses.

    Measured: Birth to 3 months

Secondary outcomes (12)
  1. Metabolite profile of human milk by Liquid Chromatography-Mass Spectrometry (LC-MS) analysis

    Human milk metabolites by LC-MS-based metabolomics. Data will be analysed as absolute concentrations of milk metabolites; how milk metabolite profiles are related to milk microbial profiles, milk oligosaccharides, infant urine metabolome, and infant fecal microbiomes will be explored using multivariate analyses.

    Measured: Birth to 3 months

  2. Milk proteome profile

    Human milk proteome by LC-MS-based, bottom-up proteomics. Data will be analysed as relative abundances of milk proteins.

    Measured: Birth to 3 months

  3. Milk protein post-translational modification (PTM) profile

    Post-translational modifications of human milk proteins is analysed by LC-MS-based and 2D- gel-based proteomics. Data will be analysed as relative abundances of milk protein PTMs.

    Measured: Birth to 3 months

  4. Milk glycome profile

    Human milk glycome by LC-MS-based glycomics. Data will be analysed as relative abundances of milk glycans.

    Measured: Birth to 3 months

  5. Microbial structure of human milk

    Human milk microbiome by nanopore sequencing. Data will be analysed as relative abundances of bacteria from phylum to genus levels.

    Measured: Birth to 3 months

  6. Microbial structure of infant feces

    Infant fecal microbiome by nanopore sequencing. Data will be analysed as relative abundances of bacteria from phylum to genus levels.

    Measured: Birth to 5 years of age

  7. Microbial structure of infant oral cavity

    Oral cavity microbiome by nanopore sequencing. Data will be analysed as relative abundances of bacteria from phylum to genus levels.

    Measured: 30 days postpartum

  8. Microbial structure of mother's skin microbiome

    Skin microbiome by nanopore sequencing. Data will be analysed as relative abundances of bacteria from phylum to genus levels.

    Measured: 30 days postpartum

  9. Metabolite profile of infant fecal material

    Infant fecal metabolome by NMR-based metabolomics. Data will be analysed as absolute concentrations of fecal metabolites

    Measured: Birth to 5 years of age

  10. Infant metabolism investigated by infant urine metabolomics

    Infant urine metabolome by NMR-based metabolomics. Data will be analysed as absolute concentrations of urine metabolites

    Measured: Birth to 3 months of age

  11. Microbial structure of maternal vagina and rectum to investigate vertical transmission of bacteria to infant during birth

    Vertical transmission of microbiome from mother to infant. Vaginal and rectal microbiome by nanopore sequencing. Data will be analysed as relative abundances of bacteria from phylum to genus levels.

    Measured: During birth

  12. Mother's 24-h dietary recall (myfood24)

    Aggregated nutrient intake data (e.g. proteins, vitamins, fibers, omega-3-fatty acids)

    Measured: During pregnancy (Gestational age 30), 30, 60, and 90 days postpartum. In each case two times within a week (one weekday and one weekend day).

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted8 Nov 2021
  2. Study start1 Jun 2019
  3. Primary completion28 Feb 2027 (estimated)
  4. Study completion30 Apr 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
168 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05111990
Sponsor's protocol ID
1-10-72-296-18
Acronym
MAINHEALTH
Status last verified
Apr 2026
First submitted
24 Sep 2021
Last updated
29 Apr 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • Overgaard Poulsen K, Astono J, Jakobsen RR, Uldbjerg N, Fuglsang J, Nielsen DS, Sundekilde UK. Influence of maternal body mass index on human milk composition and associations to infant metabolism and gut colonisation: MAINHEALTH - a study protocol for an observational birth cohort. BMJ Open. 2022 Nov 2;12(11):e059552. doi: 10.1136/bmjopen-2021-059552.

    PubMed 36323479

Questions about this trial

What is this clinical trial studying?

An observational study of Breast Milk Collection and Human Milk/Breastfeeding, run by University of Aarhus at 1 site in Denmark.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 29 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Metabolite profile of human milk (time frame: Birth to 3 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05111990, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Apr 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in